Effect of physicochemical modification on the biodistribution and tumor accumulation of HPMA copolymers

Journal of Controlled Release

Volumn 110, Issue 1, 2005, Pages 103-118

  Lammers, Twan ^a,b   Kühnlein, Rainer ^a   Kissel, Maria ^a   Subr, Vladimir ^c   Etrych, Tomas ^c   Pola, Robert ^c   Pechar, Michal ^c   Ulbrich, Karel ^c   Storm, Gert ^b   Huber, Peter ^a   Peschke, Peter ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UTRECHT UNIVERSITY   (Netherlands)

^c INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

Author keywords

Drug delivery; EPR; HPMA; Polymer therapeutics; Tumor targeting

Indexed keywords

BIODISTRIBUTION; DRUG AND PEPTIDE MOIETIES; PHYSICOCHEMICAL MODIFICATION; POLYMERIC DRUG CARRIERS; SOLID MALIGNANCY; TUMOR ACCUMULATION OF HPMA COPOLYMERS;

BIOLOGICAL ORGANS; COPOLYMERS; DRUG DOSAGE; KINETIC ENERGY; MOLECULES; TISSUE;

TUMORS;

CARBOXYL GROUP; FUNCTIONAL GROUP; HYDRAZIDE; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL MODIFICATION; CIRCULATION TIME; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG MONITORING; DRUG SYNTHESIS; DRUG TARGETING; ISOTOPE LABELING; KIDNEY; MALE; MOLECULAR WEIGHT; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROSTATE CARCINOMA; RAT; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; MALE; METHACRYLATES; MOLECULAR WEIGHT; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; POLYMETHACRYLIC ACIDS; PROSTATIC NEOPLASMS; RATS; TISSUE DISTRIBUTION;

EID: 28244435462     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2005.09.010     Document Type: Article

References (41)

1. T. Reynolds Polymers help guide cancer drugs to tumor targets-and keep them there J. Natl. Cancer Inst. 87 1995 1582 1584
2. R. Duncan The dawning era of polymer therapeutics Nat. Rev. Drug Discov. 2 2003 347 360
3. J. Kopecek, P. Kopeckova, T. Minko, Z.R. Lu, and C.M. Peterson Water soluble polymer s in tumor targeted delivery J. Control. Release 74 2001 147 158
4. B. Rihova, and K. Kubackova Clinical implications of N-(2-hydroxypropyl) methacrylamide copolymers Curr. Pharm. Biotechnol. 4 2003 311 322
5. J. Kopecek, P. Kopeckova, T. Minko, and Z. Lu HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action Eur. J. Pharm. Biopharm. 50 2000 61 81
6. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Control. Release 65 2000 271 284
7. P.A. Vasey, S.B. Kaye, R. Morrison, C. Twelves, P. Wilson, R. Duncan, A.H. Thomson, L.S. Murray, T.E. Hilditch, T. Murray, S. Burtles, D. Fraier, E. Frigerio, and J. Cassidy Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee Clin. Cancer Res. 5 1999 83 94
8. A.H. Thomson, P.A. Vasey, L.S. Murray, J. Cassidy, D. Fraier, E. Frigerio, and C. Twelves Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours Br. J. Cancer 81 1999 99 107
9. V. Bilim Technology evaluation: PK1, Pfizer/Cancer Research UK Curr. Opin. Mol. Ther. 5 2003 326 330
10. P.J. Julyan, L.W. Seymour, D.R. Ferry, S. Daryani, C.M. Boivin, J. Doran, M. David, D. Anderson, C. Christodoulou, A.M. Young, S. Hesslewood, and D.J. Kerr Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine J. Control. Release 57 1999 281 290
11. L.W. Seymour, D.R. Ferry, D. Anderson, S. Hesslewood, P.J. Julyan, R. Poyner, J. Doran, A.M. Young, S. Burtles, and D.J. Kerr Cancer Research Campaign Phase I/II Clinical Trials committee. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin J. Clin. Oncol. 20 2002 1668 1676
12. E. Gianasi, M. Wasil, E.G. Evagorou, A. Keddle, G. Wilson, and R. Duncan HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo Eur. J. Cancer 35 1999 994 1002
13. X. Lin, Q. Zhang, J.R. Rice, D.R. Stewart, D.P. Nowotnik, and S.B. Howell Improved targeting of platinum chemotherapeutics. The antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models Eur. J. Cancer 40 2004 291 297
14. J.M. Rademaker-Lakhai, C. Terret, S.B. Howell, C.M. Baud, R.F. De Boer, D. Pluim, J.H. Beijnen, J.H. Schellens, and J.P. Droz A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors Clin. Cancer Res. 10 2004 3386 3395
15. J.M. Meerum Terwogt, W.W. ten Bokkel Huinink, J.H. Schellens, M. Schot, I.A. Mandjes, M.G. Zurlo, M. Rocchetti, H. Rosing, F.J. Koopman, and J.H. Beijnen Phase I.22 clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel Anticancer Drugs 12 2001 315 323
16. Y. Kasuya, Z.R. Lu, P. Kopeckova, T. Minko, S.E. Tabibi, and J. Kopecek Synthesis and characterization of HPMA copolymer-aminopropylgeldanamycin conjugates J. Control. Release 74 2001 203 211
17. N. Nishiyama, A. Nori, A. Malugin, Y. Kasuya, P. Kopeckova, and J. Kopecek Free and N-(2-hydroxypropyl)methacrylamide copolymer-bound geldanamycin derivative induce different stress responses in A2780 human ovarian carcinoma cells Cancer Res. 63 2003 7876 7882
18. R. Satchi-Fainaro, M. Puder, J.W. Davies, H.T. Tran, D.A. Sampson, A.K. Greene, G. Corfas, and J. Folkman Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470 Nat. Med. 10 2004 255 261
19. R. Satchi-Fainaro, R. Mamluk, L. Wang, S.M. Short, J.A. Nagy, D. Feng, A.M. Dvorak, H.F. Dvorak, M. Puder, D. Mukhopadhyay, and J. Folkman Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin Cancer Cell 3 2005 251 261
20. P. Pouckova, M. Zadinova, D. Hlouskova, J. Strohalm, D. Plocova, M. Spunda, T. Olejar, M. Zitko, J. Matousek, K. Ulbrich, and J. Soucek Polymer-conjugated bovine pancreatic and seminal ribonucleases inhibit growth of human tumors in nude mice J. Control. Release 95 2004 83 92
21. R. Satchi-Fainaro, H. Hailu, J.W. Davies, C. Summerford, and R. Duncan PDEPT: polymer-directed enzyme prodrug therapy: 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination Bioconjug. Chem. 14 2003 797 804
22. A. Mitra, A. Nan, H. Ghandehari, E. McNeill, J. Mulholland, and B.R. Line Technetium-99m-Labeled N-(2-Hydroxypropyl) methacrylamide copolymers: synthesis, characterization, and in vivo biodistribution Pharm. Res. 21 2004 1153 1159
23. F. Kiessling, M. Heilmann, T. Lammers, K. Ulbrich, V. Subr, P. Peschke, B. Wängler, W. Mier, H.H. Schrenk, M. Bock, L. Schad, W. Semmler, Characterization of HE-24. 8: a polymeric contrast agent for Magnetic Resonance Angiography, submitted for publication.
24. D.M. Lubaroff, L. Canfield, T.L. Feldbush, and W.W. Bonney R3327 Adenocarcinoma of the Copenhagen rat as a model for the study of the immunologic aspects of prostate cancer J. Natl. Cancer Inst. 58 1977 1677 1689
25. L.W. Seymour, R. Duncan, J. Strohalm, and J. Kopecek Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats J. Biomed. Mater. Res. 21 1987 1341 1358
26. L.W. Seymour, Y. Miyamoto, H. Maeda, M. Brereton, J. Strohalm, K. Ulbrich, and R. Duncan Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier Eur. J. Cancer 31A 1995 766 770
27. Y. Noguchi, J. Wu, R. Duncan, J. Strohalm, K. Ulbrich, T. Akaike, and H. Maeda Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues Jpn. J. Cancer Res. 89 1998 307 314
28. M. Kissel, P. Peschke, V. Subr, K. Ulbrich, J. Schuhmacher, J. Debus, and E. Friedrich Synthetic macromolecular drug carriers: biodistribution of poly[(N-2-hydroxypropyl) methacrylamide] copolymers and their accumulation in solid rat tumors PDA J. Pharm. Sci. Technol. 55 2001 191 201
29. D.L. Livant, R.K. Brabec, K.J. Pienta, D.L. Allen, K. Kurachi, S. Markwart, and A. Upadhyaya Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma Cancer Res. 60 2000 309 320
30. K.L. Van Golen, L. Bao, G.J. Brewer, K.J. Pienta, J.M. Kamradt, D.L. Livant, and S.D. Merajver Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma Neoplasia 4 2002 373 379
31. K. Ulbrich, V. Šubr, J. Strohalm, D. Plocová, M. Jelínková, and B. Aíhová Polymeric drugs based on conjugates of synthetic and natural macromolecules: I. Synthesis and physico-chemical characterisation J. Control. Release 64 2000 63 79
32. J. Drobnik, J. Kopecek, J. Labsky, J. Rejmanova, J. Exner, V. Saudek, and J. Kalal Enzymatic cleavage of side chains of synthetic water-soluble polymers Makromol. Chem. 177 1976 2833 2848
33. B. Rihova, M. Bilej, V. Vetvicka, K. Ulbrich, J. Strohalm, J. Kopecek, and R. Duncan Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro Biomaterials 10 1989 335 342
34. J. Strohalm, and J. Kopecek Poly-[N-(2-hydroxypropyl)methacrylamide]: IV. Heterogeneous polymerization Angew. Makromol. Chem. 70 1978 109 118
35. T. Etrych, M. Jelinkova, B. Rihova, and K. Ulbrich New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties J. Control. Release 73 2001 89 102
36. L.W. Seymour, K. Ulbrich, J. Strohalm, J. Kopecek, and R. Duncan The pharmacokinetics of polymer-bound adriamycin Biochem. Pharmacol. 39 1990 1125 1131
37. W.C. Chan, and P.D. White Fmoc Solid phase Peptide Synthesis: A Practical Approach 2000 Oxford University Press
38. P.R. Salacinski, C. McLean, J.E. Sykes, V.V. Clement-Jones, and P.J. Lowry Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenyl glycoluril (Iodogen) Anal. Biochem. 117 1981 136 146
39. P.K. Singal, and N. Iliskovic Doxorubicin-induced cardiomyopathy N. Engl. J. Med. 339 1998 900 905
40. B.D. Curti Renal cell carcinoma JAMA 292 2004 97 100
41. M.B. Atkins, D.E. Avigan, R.M. Bukowski, R.W. Childs, J.P. Dutcher, T.G. Eisen, R.A. Figlin, J.H. Finke, R.C. Flanigan, D.J. George, S.N. Goldberg, M.S. Gordon, O. Iliopoulos, W.G. Kaelin Jr., W.M. Linehan, A. Lipton, R.J. Motzer, A.C. Novick, W.M. Stadler, B.T. Teh, J.C. Yang, and L. King Innovations and challenges in renal cancer: consensus statement from the first international conference Clin. Cancer. Res. 10 2004 6277S 6281S